Patient demographic information, comorbidities, laboratory data on admission, and complications from SARS-CoV-2 infection
| Demographics . | AA/AC (N = 146) . | SCT (N = 20) . | P* . |
|---|---|---|---|
| Age, y, median (range) | 64 (22-103) | 66 (22-81) | .550 |
| Male sex | 75 (52%) | 11 (55%) | .815 |
| HbS, %, mean (range) | — | 27.8 (17.8-34) | — |
| Body mass index (BMI), median (range), kg/m2 | 27.87 (16.61-69) | 28.85 (19.49-50.52) | .725 |
| Smoking history† | .091 | ||
| Current | 11 | 4 | |
| Former | 33 | 4 | |
| Never | 99 | 9 | |
| Comorbidities Patients, no. | |||
| Hypertension† | 110 | 14 | .779 |
| Obesity (BMI > 30) | 52 | 8 | .805 |
| Diabetes mellitus†,‡ | 69 | 11 | .793 |
| Chronic lung disease† | 38 | 0 | .004 |
| Coronary artery disease† | 19 | 3 | 1.00 |
| Admission Laboratory tests Median (range) | |||
| Creatinine, mg/dL | 1.15 (0.39-32.6) | 2.06 (0.56-14.3) | .004 |
| EGFR,§ mL/min/1.73 m2 | 57.84 (1.25-138.81) | 32.64 (3.20-105.01) | .014 |
| Lactate dehydrogenase, u/L† | 386 (148-966) | 330 (202-580) | .267 |
| Hemoglobin, g/dL | 12.35 (6.4-16.5) | 11.95 (5.8-17.4) | .650 |
| Platelets, cells/uL | 218.5 (6-620) | 222.5 (128-464) | .509 |
| Lymphocyte, %† | 15.4% (0-95%) | 12.1% (1-30.1%) | .203 |
| Absolute lymphocyte count, K/uL† | 1.05 (0-5.24) | 1.07 (0.39-4.97) | .605 |
| Prothrombin time, s† | 14.1 (11.9-35.8) | 14.2 (12.8-36.5) | .969 |
| Prothrombin time–international normalized ratio† | 1.1 (0.9-3.6) | 1.1 (1-3.7) | .922 |
| Partial thromboplastin time, s† | 32.4 (20.6-150) | 35.6 (30.1-150) | .111 |
| D-dimer, ng/mL† | 1681.5 (172-10 000) | 2480.5 (438-5000) | .232 |
| Fibrinogen, mg/dL† | 570.5 (303-936) | 651 (233-838) | .648 |
| C-reactive protein, mg/dL† | 78.5 (0.4-479.1) | 83.7 (0.7-300) | .517 |
| Complications Patients, no. | |||
| Respiratory compromise | .450 | ||
| None | 41 | 9 | |
| 1 to 6 L | 55 | 3 | |
| 7 to 15 L | 10 | 1 | |
| Intubation | 55 | 7 | |
| Renal complications | .532 | ||
| None | 83 | 10 | |
| Renal injury‖ | 46 | 6 | |
| Renal failure‖ | 17 | 4 | |
| Cardiomyopathy | 14 | 1 | .502 |
| Venous thromboembolism | 17 | 3 | .732 |
| Circulatory failure | 55 | 8 | 1.00 |
| Demographics . | AA/AC (N = 146) . | SCT (N = 20) . | P* . |
|---|---|---|---|
| Age, y, median (range) | 64 (22-103) | 66 (22-81) | .550 |
| Male sex | 75 (52%) | 11 (55%) | .815 |
| HbS, %, mean (range) | — | 27.8 (17.8-34) | — |
| Body mass index (BMI), median (range), kg/m2 | 27.87 (16.61-69) | 28.85 (19.49-50.52) | .725 |
| Smoking history† | .091 | ||
| Current | 11 | 4 | |
| Former | 33 | 4 | |
| Never | 99 | 9 | |
| Comorbidities Patients, no. | |||
| Hypertension† | 110 | 14 | .779 |
| Obesity (BMI > 30) | 52 | 8 | .805 |
| Diabetes mellitus†,‡ | 69 | 11 | .793 |
| Chronic lung disease† | 38 | 0 | .004 |
| Coronary artery disease† | 19 | 3 | 1.00 |
| Admission Laboratory tests Median (range) | |||
| Creatinine, mg/dL | 1.15 (0.39-32.6) | 2.06 (0.56-14.3) | .004 |
| EGFR,§ mL/min/1.73 m2 | 57.84 (1.25-138.81) | 32.64 (3.20-105.01) | .014 |
| Lactate dehydrogenase, u/L† | 386 (148-966) | 330 (202-580) | .267 |
| Hemoglobin, g/dL | 12.35 (6.4-16.5) | 11.95 (5.8-17.4) | .650 |
| Platelets, cells/uL | 218.5 (6-620) | 222.5 (128-464) | .509 |
| Lymphocyte, %† | 15.4% (0-95%) | 12.1% (1-30.1%) | .203 |
| Absolute lymphocyte count, K/uL† | 1.05 (0-5.24) | 1.07 (0.39-4.97) | .605 |
| Prothrombin time, s† | 14.1 (11.9-35.8) | 14.2 (12.8-36.5) | .969 |
| Prothrombin time–international normalized ratio† | 1.1 (0.9-3.6) | 1.1 (1-3.7) | .922 |
| Partial thromboplastin time, s† | 32.4 (20.6-150) | 35.6 (30.1-150) | .111 |
| D-dimer, ng/mL† | 1681.5 (172-10 000) | 2480.5 (438-5000) | .232 |
| Fibrinogen, mg/dL† | 570.5 (303-936) | 651 (233-838) | .648 |
| C-reactive protein, mg/dL† | 78.5 (0.4-479.1) | 83.7 (0.7-300) | .517 |
| Complications Patients, no. | |||
| Respiratory compromise | .450 | ||
| None | 41 | 9 | |
| 1 to 6 L | 55 | 3 | |
| 7 to 15 L | 10 | 1 | |
| Intubation | 55 | 7 | |
| Renal complications | .532 | ||
| None | 83 | 10 | |
| Renal injury‖ | 46 | 6 | |
| Renal failure‖ | 17 | 4 | |
| Cardiomyopathy | 14 | 1 | .502 |
| Venous thromboembolism | 17 | 3 | .732 |
| Circulatory failure | 55 | 8 | 1.00 |
P values are presented only for those features assessed at admission for at least 130 of the 166 patients.
Variable with 1 or more patients with data missing. Individuals with missing data are excluded from the table and from the statistical assessment for that variable.
Includes asthma, chronic obstructive pulmonary disease, or ILD.
EGFR calculated with the CKD-Epi equation.
Renal injury defined as Cr > 1.5 mg/dL or Cr > 50% from baseline (if known). Renal failure defined as new dialysis need.